期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 9, 期 6, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-002932
关键词
vaccination; review; immunogenicity; vaccine; immunity
资金
- University of Zurich (URPP Translational Cancer Research)
- Department of Dermatology at the University Hospital of Zurich
- Swiss National Science Found NRP 78 program [4078PO_198321]
- EU [965135]
The ongoing COVID-19 pandemic has affected millions worldwide, including vulnerable populations such as cancer patients. Currently approved mRNA vaccines appear suitable for cancer patients, but challenges exist in the vaccination process.
SARS-CoV-2 infection and the resulting COVID-19 have afflicted millions of people in an ongoing worldwide pandemic. Safe and effective vaccination is needed urgently to protect not only the general population but also vulnerable subjects such as patients with cancer. Currently approved mRNA-based SARS-CoV-2 vaccines seem suitable for patients with cancer based on their mode of action, efficacy, and favorable safety profile reported in the general population. Here, we provide an overview of mRNA-based vaccines including their safety and efficacy. Extrapolating from insights gained from a different preventable viral infection, we review existing data on immunity against influenza A and B vaccines in patients with cancer. Finally, we discuss COVID-19 vaccination in light of the challenges specific to patients with cancer, such as factors that may hinder protective SARS-CoV-2 immune responses in the context of compromised immunity and the use of immune-suppressive or immune-modulating drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据